Albireo’s Bylvay approved in EU and US for rare paediatric liver disease
PFIC is a rare and progressive liver disease affecting young children which can lead to cirrhosis and liver failure
Read More
Tag: PFIC
Shire picks up two breakthrough badges for rare disease drugs
US regulators have awarded ‘Breakthrough Therapy’ badges to two investigational products being developed by Shire: a novel formulation of budesonide for eosinophilic esophagitis and maralixibat for progressive familial intrahepatic cholestasis type 2.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
